title: Intravascular heparin protects muscle flaps from ischemia/reperfusion injury.
abstract: Heparin has been found to decrease ischemia/reperfusion injury in skeletal muscle and other tissue/organ systems. The timing of heparin administration to the muscle vasculature has not been explored. We investigated the use of heparinized blood as a washout solution during ischemia to reduce ischemia/reperfusion injury. A rat cutaneous maximus muscle free flap was subjected to a 10-hr period of room temperature ischemia, then was heterotopically transplanted to the groin via microsurgical revascularization to the femoral vessels. In three experimental groups, flaps were subjected to brief ex vivo perfusion with autologous heparinized blood, at 2, 5, or 8 hr into the 10-hr ischemic interval. In the two other groups, the flaps were not perfused, and the animals were systemically heparinized either before ischemia or before transplantation, respectively. A control group underwent no flap perfusion or systemic heparinization. After transplantation, flaps were given a 48-hr period of in vivo reperfusion, then were harvested for evaluation. Flaps undergoing ex vivo perfusion or preischemic heparinization had no significant differences in weight gain (edema) compared with flaps receiving posttransplant heparinization or no heparinization (controls). The dehydrogenase staining of muscle biopsies was significantly faster (indicative of viable tissue) for perfused flaps and the flaps for which the animals received preischemic heparinization, when compared with flaps for which the animals received posttransplant heparinization or no heparinization. From these results, we conclude that heparin offers protection from ischemia/reperfusion injury when it can be introduced into the vascular network either prior to or during the ischemia period. These findings suggest the possibility of using heparinized washout solutions to enhance survival in amputated extremities.
authors.affiliation: Department of Orthopaedic Surgery, Medical College of Wisconsin, Milwaukee 53226.
authors.forename: X
authors.initials: X
authors.lastname: Li
authors.forename: B C
authors.initials: BC
authors.lastname: Cooley
authors.forename: J D
authors.initials: JD
authors.lastname: Fowler
authors.forename: J S
authors.initials: JS
authors.lastname: Gould
mesh_terms: D000714:Anastomosis, Surgical; D000818:Animals; D001366:Axillary Artery / Q000601:surgery; D004487:Edema / Q000517:prevention & control; D005263:Femoral Artery / Q000601:surgery; D006085:Graft Survival; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D007511:Ischemia / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D008866:Microsurgery; D018482:Muscle, Skeletal / Q000098:blood supply* / Q000473:pathology / Q000637:transplantation*; D010088:Oxidoreductases / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D013524:Surgical Flaps / Q000473:pathology*; D014182:Transplantation, Autologous; D016042:Transplantation, Heterotopic; D014654:Vascular Patency
chemical_list: D006493:Heparin; D010088:Oxidoreductases